Healthcare Analysts, along with Dr. Rishi Kundi, Associate Professor of Medicine at the University of Maryland School of Medicine, provide clinical feedback on Hymacyte’s (HUMA) recently approved SYMVESS Acellular Human Vessel in Vascular Trauma on an Analyst/Industry conference call to be held on March 7 at 10 am.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Buy Rating for Humacyte Driven by Symvess Launch and Economic Advantages
- Humacyte announces issuance of U.S. patent covering Symvess manufacturing
- Promising Commercial Launch and Strategic Positioning Drive Buy Rating for Humacyte
- Humacyte announces commercial launch of Symvess
- Humacyte, Pluristyx announce expanded partnership